Review of maintenance trials for major depressive disorder: A 25-year perspective from the US food and drug administration

Journal of Clinical Psychiatry

Volumn 75, Issue 3, 2014, Pages 205-214

  Borges, Silvana ^a   Chen, Yeh Fong ^a   Laughren, Thomas P ^a   Temple, Robert ^a   Patel, Hiren D ^a   David, Paul A ^a   Mathis, Mitchell ^a   Unger, Ellis ^a   Yang, Peiling ^a   Khin, NiA ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; PLACEBO;

ADULT; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; HAMILTON SCALE; HUMAN; MAINTENANCE THERAPY; MAJOR DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL; RECURRENCE RISK; REMISSION; REVIEW;

ADULT; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WITHHOLDING TREATMENT;

EID: 84898768683     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.13r08722     Document Type: Review

References (26)

1. World Health Organization. The Global Burden of Disease: 2004 Update. http://www.who. int/healthinfo/global-burden-disease/GBD-report-2004update-fu11. pdf. Updated 2004. Accessed July 17,2013.
2. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593-602.
3. American Psychiatry Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition, http://psychiatryonline. org/data/Books/prac/PG-Depression3rdEd.pdf. Updated 2010. Accessed July 17,2013.
4. El-Mallakh RS, Briscoe B. Studies of long-term use of antidepressants: how should the data from them be interpreted? CNS Drugs. 2012;26(2):97-109.
5. Solomon DA, Keller MB, Leon AC, et al. Multiple recurrences of major depressive disorder. Am JPsychiatry. 2000;157(2):229-233.
6. Khin NA, Chen YF, Yang Y, et al. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. Clin Psychiatry. 2011;72(4):464-472.
7. Angell M. The epidemic of mental illness: why? New York Review of Booh. June 23,2011. http://www.nybooks.com/artides/archives/2011/jun/23/epidemic- mental-illness-why/?pagination=false. Accessed July 17,2013.
8. Angell M. The illusions of psychiatry. The New York Review of Books. July 14,2011. http://www.nybooks.com/artides/archives/2011/jul/14/illusions-of- psychiatry/. Accessed July 17,2013.
9. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5(2):e45.
10. Kirsch I. Antidepressants and the placebo response. Epidemiol Psichiatr Soc. 2009;18(4):318-322.
11. Krystal J. Dr Marcia Angell and the illusions of anti-psychiatry. American College of Neuropsychopharmacology Web site, http://www.acnp.org/ resources/artidediscussionDetail.aspx?cid=66dlclbf-7c40-4af9-b4f5-a3856felb5ba. Updated 2012. Accessed July 17,2013.
12. Hansen R, Gaynes B, Thieda P, et al. Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Psychiatr Serv. 2008;59(10):1121-1130.
13. Bech P. Is the antidepressive effect of second-generation antidepressants a myth? Psychol Med. 2010;40(2):181-186.
14. Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361(9358):653-661.
15. Glue P, Donovan MR, Kolluri S, et al. Meta-analysis of relapse prevention antidepressant trials in depressive disorders. Aust N Z J Psychiatry. 2010;44(8):697-705.
16. Viguera AC, Baldessarini RJ, Friedberg J. Discontinuing antidepressant treatment in major depression. Harv Rev Psychiatry. 1998;5(6):293-306.
17. Nierenberg AA, Petersen TJ, Alpert JE. Prevention of relapse and recurrence in depression: the role of long-term pharmacotherapy and psychotherapy. Clin Psychiatry. 2003;64(suppl 15):13-17.
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA: American Psychiatric Publishing; 2013.
19. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991;48(9): 851-855.
20. Kaymaz N, van Os J, Loonen AJ, et al. Evidence that patients with single versus recurrent depressive episodes are differentially sensitive to treatment discontinuation: a meta-analysis of placebo-controlled randomized trials. Clin Psychiatry. 2008;69(9):1423-1436.
21. Bech P, Lonn SL, Overa KF. Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder. Clin Psychiatry. 2010;71(2):121-129.
22. Nierenberg AA, Husain MM, Trivedi MH, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR D report. Psychol Med. 2010;40(1):41-50.
23. Judd LL, Paulus MJ, Schettler PJ, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry.2000;l57(9):150l-1501.
24. Dew MA, Reynolds CF 3rd, Mulsant B, et al. Initial recovery patterns may predict which maintenance therapies for depression will keep older adults well. J Affect Disord. 2001;65(2):155-166.
25. Pratt LA, Brody DJ, Gu Q. Antidepressant Use in Persons Aged 12 and Over: United States, 2005-2008. NCHS Data Brief 2011, no 76. Hyattsville, MD: National Center for Health Statistics; 2011.
26. Rush AJ, Kraemer HC, Sackeim HA, et al; ACNP Task Force. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology. 2006;31(9):1841-1853.